Our Research Review Committee is comprised of Summit Health physicians and staff who manage all medical clinical trials, determine the scientific/ethical merits, and identify the potential impact of clinical research on patients.
What is Clinical Research?
Also known as clinical trials, clinical research involves patients who might benefit from new treatments that are not yet available. Research physicians use clinical research to test a medication, device, treatment approach, or medication dose. All research includes a panel of experts, also known as physician investigators, who decide how best to use the new treatment. The investigators also identify the types of patients who are likely to benefit most from the treatment. To be eligible for a clinical trial, the patients must fit certain criteria.
During a clinical trial, the researchers track and make note of all the changes (data) subjects experience as a result of the treatment they are given. The data are then used to make decisions about whether to use the medication, device, or treatment for a wide range of patients.
People who participate in medical research and clinical trials are volunteers.
In general, clinical research helps determine whether:
- A new medication, device, treatment, or dose is safe and effective for a specific type of patient
- An already marketed medication or device can be used for a different disease or condition than the one for which it was originally intended
- A new medication, device, or treatment is more effective than previous treatments for a disease or condition
Medical clinical trials also sometimes compare more than one medication, device, or treatment to determine which is the most effective.
What to Expect
Better research helps researchers and practitioners understand a disease, condition, or disability as well as examine and develop ways to prevent, diagnose, treat and improve quality of life.
It is the foundation of advances in healthcare processes, treatments, and technologies.
Clinical research helps determine whether treatments are safe and effective. It is used to help improve quality of life for people who are experiencing temporary as well as ongoing (chronic) illness. Clinical research can give participants hope for overcoming a disease or condition.
Types of Clinical Research Include:
- Natural history studies to gather information about health and disease
- Screening trials to identify how to detect a disease or condition
- Diagnostic trials to determine best tests or procedures for diagnoses
- Treatment trials that include medication(s), surgery, procedures, and other therapies
- Prevention trials, including medication, vaccines, and lifestyle changes to help prevent disease from occurring and recurring
- Quality of life (or supportive care) trials to identify ways to improve quality of life for people with chronic illness
About Clinical Research
All clinical research in the United States is conducted with the review and approval of an accredited, independent review board (IRB) comprised of physicians, and statisticians. The IRB reviews each clinical trial before and during research to ensure the trial is ethical, participants’ rights are protected, and that risks are minimal.
Clinical research involves a plan known as a protocol that:
- Identifies the purpose of the trial
- Outlines who can participate (eligibility)
- Defines how long the study will last (study duration) and its phases
- Describes the treatments, including frequency and dosages of medication
- Gives details about tests and procedures
- Identifies the researchers, including a principal investigator and coinvestigator(s)
- Specifies information the researchers will gather
- Suggests whether the data will be published
Informed consent is an important part of the clinical research process. It helps people decide whether to participate in a clinical trial. During informed consent, researchers explain details of the study, including its purpose, length, treatments involved, required tests and procedures, and benefits and risks. Participants also are given contact information so that participants know whom to call to get answers to their questions. Once a trial is underway, participants continue receiving information about the trial as part of informed consent.
All participants must sign a document of informed consent to engage in clinical research.
Informed consent is not a contract. All participants for clinical research are considered volunteers who are free deny treatments, test, or procedures as well as withdraw from the study. In some cases, however, denying treatments, tests, or procedures can mean being unable to complete (or becoming ineligible for) the trial.
Our Research Team
Clinical researchers learn about disease processes when they compare healthy volunteers with patient groups in a clinical trial.
View Our SpecialistsEnrolling in Clinical Research
Before enrolling in clinical research, potential participants must qualify for it.
If you are considering enrolling in clinical research, you should consider:
- Risks, including:
- Unpleasant side effects it might cause
- Potential complications that require additional medical attention
- Visits to the study site and time it takes from your other activities
- The need for additional treatments, test, and hospital stays
- Possible costs to you for traveling to the study site
- Benefits, including:
- Having an active role in your health care
- Access to new treatments before they are available to others
- Receiving medical care and attention from doctors and other health care practitioners
- Contributing to the health and well-being of others
Once a new treatment, device, or intervention is proven safe and effective in clinical research, it can become a standard of medical practice.
For All Oncology Trials Contact Michelle Mackenzie, RN, OCN, CRC at 973-436-1755 or mmackenzie@summithealth.com. | For All Other Studies Contact Kelly Ritter, LPN, CCRC at 908-721-5673 or kritter@summithealth.com. |
Current Active Trials - Last Updated October 9, 2024
In addition to the below trials, Summit Health has access to the Tempus TIME Trial™ Program which seeks to rapidly match patients to targeted clinical trials.
Service | Type | Principal Investigator | Title | Description |
---|---|---|---|---|
Cancer Services | Gastrointestinal | Dr. David Gallinson | Metastatic colorectal cancer | Phase II open-label study to assess the safety and efficacy of stimvax® as third line therapy for metastatic colorectal cancer |
Cancer Services | Gastrointestinal | Dr. William DeRosa | Untreated Metastatic Pancreatic Cancer | An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budigalimab, Compared to Chemotherapy Alone, for the Treatment of Patients not Previously Treated for Metastatic Pancreatic Adenocarcinoma |
Cancer Services | Breast | Breast Cancer Survivors - Cognitive Impairment | NRG-CC011: Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial | |
Cancer Services | Breast | Dr. Winnie Polen | Invasive Breast Cancer or DCIS | Randomized Prospective Trial of Breast Cancer Locator Guided vs. Wire Localized Partial Mastectomy for Breast Cancer |
Cancer Services | Breast | Dr. Winnie Polen | Malignant breast tumors </=15 mm | Prospective, Multicenter Confirmatory Clinical Evaluation of Novilase® Interstitial Laser Therapy for the Focal Destruction of Malignant Breast Tumors ≤15 mm |
Cancer Services | Breast | Dr. Steven Papish | TNBC w/residual disease | A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy |
Cancer Services | Breast | Dr. Steven Papish | HER2 + Residual Breast Cancer | A011801, The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinb |
Cancer Services | Breast | Dr. Steven Papish | ER+HER2- metastatic breast cancer | A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE) |
Cancer Services | Breast | Dr. Steven Papish | Met, HER2 Low Breast Cancer | A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator’s Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) |
Cancer Services | Breast | Dr. Steven Papish | HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer | An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer |
Cancer Services | Genitourinary Oncology | Dr. William Brown | NMIBC-Unresponsive/High-Risk | EG-70 in NMIBC Patients Who Are BCG-Unresponsive and High-Risk NMIBC Patients Who Have Been Incompletely Treated With BCG or Are BCG-Naïve (LEGEND STUDY) |
Cancer Services | Genitourinary Oncology | Dr. Benjamin Freeman | Locally Advanced or Metastatic Urothelial Cancer | A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) |
Cancer Services | Genitourinary Oncology | Dr. Elan Diamond | mCRCP
| DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
Cancer Services | Genitourinary Oncology | Dr. Glen Gejerman | Prostate Cancer | Effectiveness of the SpaceOAR Vue System in Subjects with Prostate Cancer being Treated with Stereotactic Body RadiothErapy SABRE |
Cancer Services | Genitourinary Oncology | Dr. Karl Coutino | Urethral Stricture Disease Urotronic | Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters |
Cancer Services | Genitourinary Oncology | Suspected prostate cancer - Registry | Confirm mdx® for Prostate Cancer Decision Impact Trial | |
Cancer Services | Hematology | Dr. Benjamin Freeman | Untreated CLL/SLL | MK 1026 Protocol 011: A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) |
Cancer Services | Hematology | Dr. David Gallinson | Untreated CLL/SLL | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia |
Cancer Services | Hematology | Dr. Benjamin Freeman | CLL | An Open label, Multi center, Long term Extension Study of Zanubrutinib (BGB 3111) Regimens in Patients with B cell Malignancies |
Cancer Services | Hematology | Dr. Benjamin Freeman | CLL-Previously treated (Acalabrutinib) | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib |
Cancer Services | Hematology | Dr. Benjamin Freeman | R/R B-Cell Malignancies NCT05006716 | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies |
Cancer Services | Hematology | Dr. Benjamin Freeman | R/R Follicular; MZL | A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma |
Cancer Services | Hematology | Dr. Benjamin Freeman | Waldenström Macroglobulinemia Observational | A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia |
Cancer Services | Hematology | Dr. David Gallinson | Warm Autoimmune Hemolytic Anemia (wAIHA) | A phase 3, randomized, double-blind, study to assess efficacy and safety of ianalumab (VAY736) versus placebo in warm autoimmune hemolytic anemia (wAIHA) patients who failed at least one line of treatment (VAYHIA) |
Cancer Services | Hematology | Dr. David Gallinson | Primary Immune Thrombocytopenia (ITP) | A phase III, randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAYHIT1) |
Cancer Services | Hematology | Dr. David Gallinson | R/R Primary Immune Thrombocytopenia (ITP) | A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltrombopag in patients with primary immune thrombocytopenia (ITP) who had an insufficient response or relapsed after first line steroid treatment (VAYHIT2) |
Cancer Services | Thoracic | Dr. Sarada Gurubhagavatula | NSCLC w/KRAS G12C 1st line | A Global Pivotal Study in Patients with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of Pembrolizumab and LY3537982 vs Pembrolizumab and Placebo in those with PD-L1 ≥ 50% or Pembrolizumab, Pemetrexed, Platinum Chemotherapy and LY3537982 vs Pembrolizumab, Pemetrexed, Platinum Chemotherapy and Placebo regardless of PD-L1 Expression |
Cancer Services | Thoracic | Dr. Sarada Gurubhagavatula | NSCLC - 2nd Line | A randomized, phase 3, open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer |
Cancer Services | Thoracic | Dr. Sarada Gurubhagavatula | NSCLC | An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD |
Cancer Services | Thoracic | Dr. Sarada Gurubhagavatula | Early Stage II-IIIb NSCLC | A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination with Chemotherapy versus Cemiplimab in Combination with Chemotherapy in Patients with Resectable Early Stage (Stage II to IIIB [N2]) NSCLC |
Cancer Services | Thoracic | Dr. Sarada Gurubhagavatula | COMING SOON mNSCLC w/EGRFm | AstraZeneca, D516KC00001, A Phase III, Open Label, Sponsor-Blind, Randomized Study of Dato DXd With or Without Osimertinib Versus Platinum-Based Doublet Chemotherapy for Patients with EGFR-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed on Prior Osimertinib Treatment (TROPION-Lung15), 284004 |
Cancer Services | Thoracic | Dr. Sarada Gurubhagavatula | COMING SOON Met. NSCLC - 1st Line XmAb717-06 | A Phase 1b/2, Open-label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced Non-small Cell Lung Cancer |